It was reported that the combination of empagliflozin (SGLT2 inhibitors) and linagliptin (a DPP-4 inhibitor) could provide more effective hypoglycemic effects than monotherapy in patients who did not respond to metformin, with a lower risk of hypoglycemia (92). The gene discussed is SLC5A2; the disease is Hypoglycemia.